- 4-Week # shares sold: 5,000
- 12-Week # shares sold: 14,671
- 24-Week # shares bought: 700,000
- 24-Week # shares sold: 30,671
Citi lowered Portola Pharmaceuticals' (PTLA) stock rating to 'neutal' this morning.
The FDA asked Portola Pharmaceuticals (PTLA) to provide more information on a new anticoagulation reversal drug.
Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a strong on high relative volume candidate